2024 Annual Report and Audited Financial Statements

The year 2024 marked a major turning point for AMM-Only Project. It was defined by continued progress on the clinical trial of SQY51, a promising drug candidate developed by SQY Therapeutics which was co-founded and financed by the association. The year also brought strengthened governance, the launch of a new endowment fund to scale our impact and prepare for the future, the expansion of our operational team, and nearly 30 million euros raised through Only Watch. All of these milestones are detailed in the 2024 Annual Report, available in both French and English.

In a global context marked by uncertainty, funding scientific research has never been more essential. This report is a testament to our commitment to supporting, with both rigor and ambition, the scientists who work every day to find a treatment for Duchenne muscular dystrophy and other neuromuscular diseases.

The association is also proud to share its 2024 financial statements, which have been certified by an independent auditor, Mr. Christian Boisson, of the firm Grant Thornton Monaco.